MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma

Phase 2
Active, not recruiting
Conditions
Asthma
Interventions
First Posted Date
2024-07-01
Last Posted Date
2024-07-03
Lead Sponsor
Università degli Studi di Ferrara
Target Recruit Count
80
Registration Number
NCT06482294
Locations
🇮🇹

Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy

Deciphering a Novel and Unique Brown Adipose Tissue Depot in Women

Not Applicable
Not yet recruiting
Conditions
Cardiometabolic Diseases
Interventions
Behavioral: Thermoneutral condition
Behavioral: Cold condition
Drug: Salbutamol
Behavioral: Aerobic exercise condition
First Posted Date
2024-05-23
Last Posted Date
2024-05-23
Lead Sponsor
Universidad de Almeria
Target Recruit Count
40
Registration Number
NCT06426082
Locations
🇪🇸

Universidad de Almería, Almería, Spain

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Phase 4
Recruiting
Conditions
Asthma
Interventions
First Posted Date
2024-05-21
Last Posted Date
2025-01-08
Lead Sponsor
AstraZeneca
Target Recruit Count
2000
Registration Number
NCT06422689
Locations
🇺🇸

Research Site, Greenville, North Carolina, United States

The Regulatory Function of Inhaled Asthma Medication Salbutamol on Thermogenesis

Early Phase 1
Not yet recruiting
Conditions
Effect of Asthma Medication Salbutamol on Obesity
Interventions
First Posted Date
2024-03-19
Last Posted Date
2024-03-19
Lead Sponsor
Tongji University
Target Recruit Count
30
Registration Number
NCT06319183

Nebulized Salbutamol in Acute Renal Colic

Not Applicable
Not yet recruiting
Conditions
Renal Colic
Interventions
First Posted Date
2024-02-23
Last Posted Date
2024-03-19
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
214
Registration Number
NCT06276231

Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy

Phase 4
Not yet recruiting
Conditions
Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
Interventions
First Posted Date
2023-12-06
Last Posted Date
2023-12-06
Lead Sponsor
Assiut University
Target Recruit Count
87
Registration Number
NCT06158893

Video Assisted Study of Salbutamol Response in Viral Wheezing

Recruiting
Conditions
Wheezing
Interventions
First Posted Date
2023-10-23
Last Posted Date
2024-01-22
Lead Sponsor
University of Oulu
Target Recruit Count
50
Registration Number
NCT06093152
Locations
🇫🇮

Department of Pediatrics, Oulu University Hospital, Oulu, Finland

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Phase 3
Recruiting
Conditions
Asthma
Interventions
First Posted Date
2023-09-25
Last Posted Date
2025-01-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
2196
Registration Number
NCT06052267
Locations
🇺🇸

Teva Investigational Site 15764, South Dartmouth, Massachusetts, United States

🇦🇷

Teva Investigational Site 20109, Bahia Blanca, Argentina

🇺🇸

Teva Investigational Site 15581, Paradise Valley, Arizona, United States

and more 315 locations

5 Versus 10 Units of Insulin in Hyperkalemia Management

Phase 4
Recruiting
Conditions
Hyperkalemia
Electrolyte Imbalance
Potassium Imbalance
Electrolyte Disturbance
Interventions
First Posted Date
2023-09-14
Last Posted Date
2023-10-03
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
336
Registration Number
NCT06036823
Locations
🇴🇲

Sultan Qaboos University hospital, Seeb, Muscat, Oman

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Salbutamol 400mcg
Drug: Budesonide/formoterol
Drug: Placebo
First Posted Date
2023-09-07
Last Posted Date
2025-01-08
Lead Sponsor
University of Alberta
Target Recruit Count
90
Registration Number
NCT06027606
Locations
🇨🇦

Clinical Physiology Laboratory, Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath